British Pharmacopoeia 2010 Newsletter


T




                                                                            ...
BP20I0
                Global Sales of the BP 2009                           India has become a massive growth market
    ...
BP20I0
                                                   Globally, sales of the BP are increasing, and
  Globally, sales ...
BP20I0
                                 Flexible options                                                   Thank you for t...
Upcoming SlideShare
Loading in …5
×

British Pharmacopoeia 2010 Newsletter

722
-1

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
722
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

British Pharmacopoeia 2010 Newsletter

  1. 1. British Pharmacopoeia 2010 Newsletter T BP20I0 he British Pharmacopoeia (BP) 2010 has now published and to mark the occasion here is the second edition of the BP Newsletter. In this edition you will find useful information on sales of the BP 2009, providing you with a global picture of BP sales and opportunities that we have for building on these in the future. We also reveal exactly what is involved in the BP production process, providing you with an insight into how long it takes to print and how much paper is used to create the finished copies required for publication. The BP 2010 - Now Published The BP 2010 in Production As the only official source of British The production process for the British Pharmaceutical standards, the 2010 edition is Pharmacopoeia is one of the biggest jobs of the the essential reference for any individual or year for TSO, the publishers of the BP. The organisation working within pharmaceutical printing and binding process takes eight weeks research and development, manufacturing and to complete from start to finish. This is simply the testing worldwide. production stage though, work on the content of the new BP begins almost as soon as the current Now is the time to alert your customers that they year is signed off and ready to go to press. need to purchase their copies of the British Pharmacopoeia 2010. This will allow them enough time to observe the new standards and comply with the legally effective date of 1 January 2010. New for 2010 • 40 new monographs and formulated preparations • New and revised monographs for Herbal and Complementary Medicines • Additional standards for widely used unlicensed formulations • European Pharmacopoeia 6th edition material up to and including Supplement 6.5 • Three updates to the content of the BP 2010 Online to harmonise with the European The printing of the BP involves the purchase of Pharmacopoeia. over 40 tonnes of paper, supplied on reels that amount to almost 786 kilometres (almost 489 miles) in length, which would take nearly 10 hours to drive by car! Delivery of the finished product, due to its size, requires 85 pallets and four articulated lorries. Many individuals are involved in the production of the BP; including those working within editorial, project delivery, data analysts, printers, binders, the planning co-ordinator, project manager and staff working within the press where the BP is printed. The process requires all of these individuals to work within a structured timeframe to ensure that the new edition of the BP publishes on time and is dispatched to you and your customers immediately upon ordering. British Pharmacopoeia Newsletter August 2009 1
  2. 2. BP20I0 Global Sales of the BP 2009 India has become a massive growth market for the British Pharmacopoeia in recent years The BP 2009 edition has now been published with sales increasing by 114% since the 2004 for a year, providing a clear picture of the global edition. It was the biggest single country spread of the BP and the countries in which market for the BP 2009, this was significantly sales are showing a visible growth. As a reseller, helped by the appointment of Educational this information will provide you with a more Book Centre (Mumbai) as our exclusive Indian informed picture of BP sales and the countries reseller last year. Educational Book Centre in which we can work together to further have been working very hard to grow sales develop your sales. throughout 2009. The next five years will see pivotal change in the Indian pharmaceutical market as the leading companies strive towards South Korea’s sales of the BP have international competitiveness. Domestic pharmaceutical sales stood at $6.2 billion at grown by 63% since the 2007 edition. the end of 2006 and are expected to grow at a rate of 9.5 – 10% annually, to reach £16 billion, The Far East has shown itself to be one of the by 2015. BP’s biggest growth territories throughout 2009, with a substantial increase on sales in South America continues to be a growth market 2008. Countries within the Far East that have for the BP with sales increasing by 72% on the performed particularly well include Japan, 2008 edition. The key markets of Costa Rica, Singapore and South Korea. South Korea’s El Salvador, Guatemala, Honduras, Mexico, sales of the BP have grown by 63% since the Nicaragua and Panama alone represented a 2007 edition. There is also huge opportunity combined pharmaceutical market of $18.1 to grow the market in China, a country which is billion in 2008. Pharmaceutical producers face increasingly being seen as a place to conduct increasing regulatory changes, particularly in R&D and clinical trials for pharmaceuticals. Mexico. Local manufacturing requirements will be Improvements in drug registration, combating phased out by August 2010, which is expected to counterfeiting and general healthcare provision, increase generic competition. As a result of these if addressed successfully, could make China an developments Central and Southern America even more influential pharmaceutical market offer significant potential to both local and and customer for the BP. international pharmaceutical producers, and in turn to increasing sales of the BP. Germany remains a dominant country within Europe for sales of the BP, no doubt aided by the hard work of our exclusive resellers in the territory, Deutscher Apotheker Verlag. Germany represents the largest generic pharmaceutical market in Europe, both in terms of size and the level of generic penetration. Germany is also one of the largest drug exporters in the world, with shipments valued at US $51.6 billion in 2007. Sales of the BP 2009 in the UK remain steady but there is always potential to increase this, in line with its position as one of the leading pharmaceutical producers and exporters. The Eastern European pharmaceuticals market is expected to grow to reach a value of $41.4bn in 2014. 2 British Pharmacopoeia Newsletter August 2009
  3. 3. BP20I0 Globally, sales of the BP are increasing, and Globally, sales for the BP with the forecast that the global pharmaceutical are increasing, and with market is set to grow to $929 billion in 2012 there is a strong platform from which the BP can the forecast that the global continue to strengthen its position as a leading pharmaceutical market is set worldwide pharmaceutical standard. Emerging to grow to $929 billion in 2012 or ‘pharmerging’ markets will also contribute significantly to the growth of BP sales in the there is a strong platform from next few years. Collectively, these emerging which the BP can continue markets – Brazil, Mexico, China, India, Russia, to strengthen its position as Turkey and South Korea – are predicted to see compound annual growth rates of 13-16% by a worldwide pharmaceutical 2013. These figures prompted David Campbell, standard. IMS’s (provider of global healthcare intelligence) senior principle for emerging markets, to declare that what we are about to see is a ‘new The Eastern European pharmaceuticals world order’ by 2013, with China becoming a market is expected to grow to reach a value top 3 market. of $41.4bn in 2014. Romania recorded the highest growth in pharma sales over the Sources The Eastern European Pharmaceutical Market Outlook to 2010, 2006-07 period (44.6%), followed by Slovakia Companiesandmarkets.com and OfficialWire. (37.1%). It is anticipated these markets will The Outlook for Emerging Central American Pharmaceutical Markets, continue to develop by increasing access to espicom modern medicines and as regional branded The Pharmaceutical Market: China, espicom generic manufacturers enter the market. BP The Pharmaceutical Market: Germany, espicom 2009 sales in Eastern Europe are stable, but Pharmaceutical Market Trends, 2008-2012, piribo there is scope to develop this with BP 2010 The Right Spice, Pharmaceutical Market Entry in India, Deloitte as the market grows. Poland’s sales of the BP The World Pharmaceutical Markets Fact Book 2007, espicom account for a third of Eastern Europe’s, with ‘Pharmerging’ markets and the new world order, Pharmaceutical Executive, June 2009. Slovenia also seeing strong sales as the second largest territory. Combined, these two countries account for 55% of sales in the Eastern European market. Macedonia and Estonia also purchased the BP in 2009, revealing themselves as countries in which we can build sales of the BP 2010. Emerging or ‘pharmerging’ markets will also contribute significantly to the growth of BP sales in the next few years. British Pharmacopoeia Newsletter August 2009 3
  4. 4. BP20I0 Flexible options Thank you for taking the time to read this BP Newsletter. We hope the information • British Pharmacopeia 2010 package included helps you sell the BP 2010 to your - Five volume printed edition customers. We welcome feedback and would - Single-user licence for the CD-ROM like to hear from you if there is a particular BP - Single-user licence for the online version related topic that you would like us to cover in via www.pharmacopoeia.co.uk future editions. In the next edition of the BP - Three free updates to the BP 2010 Newsletter we will be launching ‘Reseller in Online to harmonise with the European Focus’, providing you with the opportunity to tell Pharmacopoeia other companies about who you are and, most - £830 importantly, your experience of selling the BP. If - ISBN 9780113228287. you would like to take part in this please contact us at pharmahealth@tso.co.uk. • eBook - Exclusively available to BP 2010 print How to order customers - Enables access to the full five volume To place your order for the British set of the BP on a PDA or any other Pharmacopoeia 2010 please contact: compatible device - £398 (£457.70 inc VAT) All non-UK customers: - ISBN 9780113228461. Sophie O’Reirdan Tel: +44 (0)20 7873 8424 • Concurrent-user licence Email: sophie.oreirdan@tso.co.uk - Simultaneous access to the BP online across an organisation All UK customers: - A legal requirement if the BP is being TSO UK Trade Sales used on more than one workstation Tel: +44 (0)1603 69 6876 - Contact our specialist team at Email: key.trade@tso.co.uk pharmahealth@tso.co.uk. To enquire about concurrent user licences • Standing order contact: - A time efficient solution that ensures Tel: +44 (0)1603 69 6701 your customers receive future editions Email: pharmahealth@tso.co.uk of the BP as soon as they are published - The most effective way for your Don’t forget, TSO can keep you informed of the customers to remain compliant. latest health and pharmaceutical titles. Register to receive email updates by visiting • Consortia pricing www.tso.co.uk/signup. - Available on request for academic organisations - UK-based organisations should contact pharmahealth@tso.co.uk - Non-UK based organisations should contact sophie.oreirdan@tso.co.uk 6225 08/09 Prices, images and publication dates are correct at the time of going to press but may be subject to change without notice. The Stationery Office Ltd. Company Registered Number 3049649. Registered office: Clifton House, Worship Street, London, EC2A 2EJ. DVH 4 British Pharmacopoeia Newsletter August 2009

×